Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

McMaster University

$30,000.00

Ripple Therapeutics partnership for development and testing of drug delivery system_x000d_ _x000d_

EF 2020-21

Résumé
Ripple Therapeutics, a spin out company located in Toronto ON, has a novel method of delivering dexamethasone, a corticosteroid, the eye. The drug delivery system does not involve the use of polymeric excipients, providing superior control over the release of drug. Ongoing work on this system involves the development of prototype materials that release dexamethasone at different concentrations and at different rates. The Sheardown lab at McMaster University in partnership with Ripple will develop new dexamethasone containing systems which show release rates that can be tailored for the application. This will be important as the team develops an understanding of therapeutically relevant concentrations. The systems will be characterized for drug release as well as biocompatibility and drug distribution in the eye. Ultimately, this system will be moved forward through the Ripple pipeline for the treatment of various ocular conditions, including uveitis, which is difficult to treat with current dosage forms.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
560692-2020
Name nom
Sheardown, Heather
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
30000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
508
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Polymers, rubber and plastics
Area of application fr
Polymères, caoutchouc et plastiques
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Ripple Therapeutics partnership for development and testing of drug delivery system_x000d_ _x000d_
Keyword
NSERC
Application summary
Ripple Therapeutics, a spin out company located in Toronto ON, has a novel method of delivering dexamethasone, a corticosteroid, the eye. The drug delivery system does not involve the use of polymeric excipients, providing superior control over the release of drug. Ongoing work on this system involves the development of prototype materials that release dexamethasone at different concentrations and at different rates. The Sheardown lab at McMaster University in partnership with Ripple will develop new dexamethasone containing systems which show release rates that can be tailored for the application. This will be important as the team develops an understanding of therapeutically relevant concentrations. The systems will be characterized for drug release as well as biocompatibility and drug distribution in the eye. Ultimately, this system will be moved forward through the Ripple pipeline for the treatment of various ocular conditions, including uveitis, which is difficult to treat with current dosage forms.